Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,Carlton G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Fred K. L. Spijkervet,Michael T. Brennan,Salivary Gland Hypofunction,Xerostomia Section +24 more
Reads0
Chats0
TLDR
There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment.Abstract:
This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.read more
Citations
More filters
Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
TL;DR: Salivary gland hypofunction and xerostomia are induced by radiotherapy in the head and neck region depending on the cumulative radiation dose to the gland tissue, and treatment focus should be on optimized/new approaches to further reduce the doses to the parotids.
Journal ArticleDOI
Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers
Arjan Vissink,James B. Mitchell,Bruce J. Baum,Kirsten H. Limesand,Siri Beier Jensen,Philip C. Fox,Linda S. Elting,Johannes A. Langendijk,Robert P. Coppes,Mary E. Reyland +9 more
TL;DR: This review addresses the pathophysiology underlying irradiation damage to salivary gland tissue, the consequences of radiation injury, and issues contributing to the clinical management of salivARY gland hypofunction and xerostomia.
Journal ArticleDOI
Interventions for the management of dry mouth: topical therapies.
TL;DR: There is no strong evidence from this review that any topical therapy is effective for relieving the symptom of dry mouth, and both integrated mouthcare systems and oral reservoir devices show promising results but there is insufficient evidence at present to recommend their use.
Journal ArticleDOI
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Noam Yarom,Noam Yarom,Charles L. Shapiro,Douglas E. Peterson,Catherine Van Poznak,Kari Bohlke,Salvatore L. Ruggiero,Salvatore L. Ruggiero,Cesar A. Migliorati,Aliya Khan,Archie Morrison,Archie Morrison,Holly Anderson,Barbara A. Murphy,Devena E. Alston-Johnson,Rui Amaral Mendes,Beth M. Beadle,Siri Beier Jensen,Deborah P. Saunders +18 more
TL;DR: In this paper, the authors provide guidance regarding best practices in the prevention and management of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer.
Journal ArticleDOI
Treatment of late sequelae after radiotherapy for head and neck cancer
Primož Strojan,Katherine A. Hutcheson,Avraham Eisbruch,Jonathan J. Beitler,Johannes A. Langendijk,Anne W.M. Lee,June Corry,William M. Mendenhall,Robert Smee,Alessandra Rinaldo,Alfio Ferlito +10 more
TL;DR: The available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients is reviewed, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.
References
More filters
Journal ArticleDOI
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
Graeme Duncan,Joel B. Epstein,Dongsheng Tu,Samy El Sayed,Andrea Bezjak,Jon Ottaway,Joe Pater +6 more
TL;DR: The National Cancer Institute of Canada Clinical Trials Group undertook a multicenter, randomized, double‐blind controlled trial of an oral antimicrobial versus placebo to prevent and treat mucositis, and the quality of life (QOL) analysis is presented.
Journal ArticleDOI
Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment.
M Blom,T Lundeberg +1 more
TL;DR: This study shows that acupuncture treatment results in statistically significant improvements in SFR in patients with xerostomia up to 6 months and suggests that additional acupuncture therapy can maintain this improvement in S FR for up to 3 years.
Journal ArticleDOI
Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
Tai Xiang Lu,Wei Yuan Mai,Wei Yuan Mai,Bin S. Teh,Chong Zhao,Fei Han,Yin Huang,Xiao Wu Deng,Li Xia Lu,Shao Min Huang,Zhi Fan Zeng,Cheng Guang Lin,Hsin H. Lu,J. Kam Chiu,L. Steven Carpenter,Walter H. Grant,Shiao Y. Woo,Nan Ji Cui,E. Brian Butler +18 more
TL;DR: The improvement in tumor target coverage and significant sparing of adjacent critical structures allow the feasibility of IMRT as a retreatment option for recurrent NPC after initial conventional RT to be considered.
Journal ArticleDOI
Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials
John W. Rieke,Mark D. Hafermann,Jonas T. Johnson,Francis G. LeVeque,Ryan Iwamoto,Barry W. Steiger,Charles C Muscoplat,Susan C. Gallagher +7 more
TL;DR: It is concluded that in these studies pilocarpine produced clinically significant benefits with acceptable side effects and risks for the treatment of symptomatic postradiation xerostomia.
Journal ArticleDOI
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.
Nancy Y. Lee,W O'Meara,Kelvin Chan,Cesar Della-Bianca,James Mechalakos,J. Zhung,Suzanne L. Wolden,Ashwatha Narayana,Dennis H. Kraus,Jatin P. Shah,David G. Pfister +10 more
TL;DR: In this article, the authors performed a retrospective review of laryngeal/hypopharygeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT).
Related Papers (5)
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more